Early dissemination of bevacizumab for advanced colorectal cancer: a prospective cohort study

BMC Cancer

Table 3 Percent of patients who received first-line bevacizumab by selected patient characteristics

Characteristic*	Received first-line bevacizumab (n = 110)	Unadjusted p-value^#
	%
Age (years)		0.007
< 55	41
55-64	32
65-74	30
≥ 75	16
ACE-27 Comorbidity Index (score)		0.831
None (0)	29
Mild (1)	30
Moderate (2)	35
Severe (3)	34
Race		0.403
Non-white	28
White	33
Gender		0.005
Female	41
Male	26
Insurance		0.005
Private	41
Public	20
Medicare + supplemental	32
Veterans Administration	21
Missing	21
Health system		0.050
Fee-for-service	35
Integrated health system	25
Geographic region		0.003
West/Midwest	23
Southern	35
Atlantic	43
Annual household income		0.127
< $20,000/year	25
≥ $20,000/year	34
Missing	30
Diagnosis of metastatic disease		0.532
Stage IV at diagnosis	30
Recurrence	35
Did anyone mention that enrollment in a clinical trial might be an option for you?		0.152
Yes	38
No	28
Missing	35
How often do you read books, magazines or newspapers?		0.111
Often	35
Rarely	24
Missing	26
After talking with your doctors about chemotherapy, how likely did you think it was that chemotherapy would have side-effects or complications?		0.133
Likely	33
Not likely	24
Missing	30

*The composition of health systems in the categorization of fee-for-services vs. integrated health systems has been previously described [8]. Comorbidity was calculated using the Adult Comorbidity Evaluation-27 (ACE-27) index [11]. The cardiovascular comorbidities were collected as a part of the ACE-27. ^#Unadjusted p-values for aggregate variable effects (type 3 Wald statistics).

ISSN: 1471-2407